Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone
NCT05726903Phase 4Completed
- Sponsor
- University of Colorado Denver
- Start
- Dec 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of medroxyprogesterone acetate in gender dysphoria (GD), sponsored by University of Colorado Denver. Primary endpoints: Number of Participants Satisfied With Self-Administered DMPA at Initiation at 6 months and Number of Participants Satisfied With DMPA in an Office Setting at 2 months. Started Dec 2022; status: completed.
02
Drugs
medroxyprogesterone acetate
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NCT05726903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726903.